Second Dicerna Hepatic Disease Target Option Exercise
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target  From Research Collaboration with Dicerna Collaboration seeks to develop novel treatments for chronic liver diseases,  including nonalcoholic steatohepatitis (NASH)  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 4, 2019 Category: Research Source Type: news

Collaboration with Vanderbilt University
Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders  Boehringer Ingelheim Enhances Central Nervous System Disease PipelineVanderbilt Center for Neuroscience Drug Discovery Advances Preclinical Schizophrenia Targets   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 3, 2019 Category: Research Source Type: news

Virtual clinical trial collaboration with Science 37
Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the Development of Novel Therapies  Boehringer Ingelheim collaborates with Science 37 to accelerate the clinical development of new therapies worldwide  Science 37 ’s technology enables patients to remotely participate in clinical studies, which enables increased patient diversity, study efficiency and speed, while decreasing patient burden (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 3, 2019 Category: Research Source Type: news

Inauguration_facility_children_with_multiple_disabilities
Boehringer Ingelheim and the Muskan Foundation inaugurate facility for children with multiple disabilities  New Facility is'first-of-its-kind'at B.J. Wadia Children ’s Hospital, Disability Centre in Mumbai, India Special educational programs will train children with Multiple Disabilities with Visual Impairment (MDVI)  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 17, 2018 Category: Research Source Type: news

A tool to aid in the prevention of African swine fever
Boehringer Ingelheim launches a tool to aid in the prevention of African swine feverASF COMBAT is an online management and biosecurity assessment tool aimed at reducing the African swine fever (ASF) introduction risk levelBoehringer Ingelheim reconfirms its commitment to developing new innovative solutions to address current challenges   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 14, 2018 Category: Research Source Type: news

VARGADO data
Vargatef ® plus docetaxel could be an option after failure of immunotherapy in lung cancerResults from a real-world study1  support a recent update to the ESMO guidelines2 recommending nintedanib (Vargatef®) plus docetaxel following first-line chemotherapy (+/- immunotherapy) in advanced NSCLC of adenocarcinoma histology (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 13, 2018 Category: Research Source Type: news

Boehringer Ingelheim vaccinates over 100 billion birds with VAXXITEK since 2006
Boehringer Ingelheim vaccinates over 100 billion birds with VAXXITEK ® HVT + IBD since 2006VAXXITEK ® HVT + IBD provides a life-long immunity against Infectious bursal disease and Marek's diseaseIt is the first vector vaccine to have been launched on the avian marketVAXXITEK ® HVT + IBD is registered in more than 75 countries  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 12, 2018 Category: Research Source Type: news

Boehringer Ingelheim and GST prepared bring innovation to equine market
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine marketFirst-ever veterinary stem cell medicine recommended for EU marketing authorisationArti-Cell Forte provides a unique ready-to-use solution for the treatment of equine lamenessBoehringer Ingelheim again demonstrates its commitment to continuous innovation  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 7, 2018 Category: Research Source Type: news

LastMile initiative to address barriers in animal healthcare
Boehringer Ingelheim launches ‘LastMile’ initiative to address major barriers in animal healthcare sector in Sub-Saharan AfricaThe initiative is established by Boehringer Ingelheim and supported by GALVmed (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 3, 2018 Category: Research Source Type: news

Two new claims for Nexgard range in EU and Australia
Boehringer Ingelheim announces two new claims for Nexgard ® and Nexgard Spectra® in the EU and AustraliaBoehringer Ingelheim expands the label claims of its NexGard ® brands for the treatment of two severe skin diseases in dogs in the EU and in AustraliaBy broadening the range, Boehringer Ingelheim contributes to the improvement of dogs ’ health globally (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 23, 2018 Category: Research Source Type: news

Empa ACC Expert Consensus Decision Pathway
American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 23, 2018 Category: Research Source Type: news

Survey with Ipsos to gain insights human-animal bond
Boehringer Ingelheim partners with Ipsos to gain insights on human-animal bond in EuropeThe human-animal bond survey assigned to the global Research Institute Ipsos took place in 2017 in five European countries, targeting 3,000 pet ownersThe survey results show a strong positive impact of pet relationship on owners'well-beingVeterinarians prove to be the contact of choice to provide information on the topic (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 21, 2018 Category: Research Source Type: news

Epizyme_Collaboration
Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies  Boehringer Ingelheim Expands Biomarker-driven Oncology Programs   Alliance Enhances Epizyme ’s Leadership in Oncology Epigenetics  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 15, 2018 Category: Research Source Type: news

Official partner to Cat Care for Life
Boehringer Ingelheim becomes an official partner to CatCareforLifeTheCatCareforLife program is a new worldwide initiative set up by the International Society of Feline MedicineIt aims to encourage cat owners to work with their veterinary clinics to maintain cats in the peak of health through all their life stagesBoehringer Ingelheim is committed to further improving the health and well-being of cats and helping educate veterinarians and cat owners (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2018 Category: Research Source Type: news

Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Empagliflozin was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors1Effect of empagliflozin on HHF was consistent in patients with and without established cardiovascular disease1Findings support data from the landmark EMPA-REG OUTCOME ® trial, in which empagliflozin reduced the relative risk of HHF by 35 percent in people with type 2 diabetes and established cardiovascular disease2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2018 Category: Research Source Type: news

Extension_BioXcellence_Fremont
Boehringer Ingelheim achieves next expansion milestone in biologics production in the USCulmination of a €200 million investment in CaliforniaWorldwide capacity for manufacturing biopharmaceutical medicines now exceeds 290,000 litersGlobal manufacturing network for products in Boehringer Ingelheim ’s own research pipeline and for contract manufacturing (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 30, 2018 Category: Research Source Type: news

New working environment for agile working methods
Boehringer Ingelheim inaugurates new centre for agile working methods: more and better health solutions for humans and animalsNew building inaugurated exclusively for agile working methods in IngelheimAgile Facilitators strengthen Boehringer Ingelheim from ideation to development of scalable solutions for human and animal health  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 25, 2018 Category: Research Source Type: news

Winners of 2018 BVDzero Case Awards
Boehringer Ingelheim announces the winners of 2018 BVDzero Case AwardsBoehringer Ingelheim grants a total prize of 15,000  euros to the top 10 clinical casesBoehringer Ingelheim encourages the search for both clinical and subclinical cases of bovine viral diarrhea (BVD) in cattle herds, aiming to improve BVD awareness (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 19, 2018 Category: Research Source Type: news

GioTag_sequencing_results
Real-world study shows using Giotrif ®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLCGioTag is the first global, real-world study to evaluate the sequencing of targeted treatments in patients with the most common acquired treatment resistance mutation1  Results published today in Future Oncology1   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 18, 2018 Category: Research Source Type: news

Results from two Pradaxa trials to be presented at WSC
Results from Pradaxa ® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke CongressData from key trials will aid in increasing scientific understanding of ESUS and CVTRESPECT-ESUS is first randomised trial to investigate clinical profile of Pradaxa ® vs ASA (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 12, 2018 Category: Research Source Type: news

health project elephants
Boehringer Ingelheim increases awareness of health with the micro enterprise project ‘Elephants’ in South IndiaBoehringer Ingelheim launches new health project in Coimbatore/IndiaProject to raise awareness about infections with communicable diseases due to bad hygiene and the importance of handwashing with soap  Trainings will enable participants to start own soap manufacturing business (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 12, 2018 Category: Research Source Type: news

Inauguration of new global center for veterinary vaccine R & D
Boehringer Ingelheim inaugurates its new global centre for veterinary vaccine R&D in Lyon, France70 million euro investment reinforces the company ’s leading position in the veterinary vaccine marketThe new R&D center of 14,500 square meters is a high-tech facility employing more than 200 employees (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 10, 2018 Category: Research Source Type: news

2018 Animal Welfare Medals
: Boehringer Ingelheim recognizes outstanding research in animal healthBoehringer Ingelheim honors research papers on innovative health solutions for improving animal welfareIndependent jury awards prizes in the folowing categories: cattle, equine, swine, as well as small animals and petsThe  awards demonstrate focus on prevention, animal well-being and innovative solutions (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 10, 2018 Category: Research Source Type: news

Empa T1D Full Data
Boehringer Ingelheim and Lilly present full results from EASE Phase III programme for empagliflozin as adjunct to insulin in type 1 diabetesAll investigated doses met the primary efficacy endpoint defined as a change from baseline in HbA1c versus placebo after 26 weeks of treatment  Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes  Full results presented at the 54th European Association for the Study of Diabetes Annual Congress (EASD) and published online in Diabetes Care ahead of print1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 4, 2018 Category: Research Source Type: news

Boehringer Ingelheim is committed to joining forces in the global fight against rabies
The company ’s goal is to bring attention to the serious threat that rabies still poses to animals and humans in many parts of the worldAn estimated 160 people die from rabies every day, 40 per cent of whom are children1Human rabies deaths could be avoided through effective dog vaccination1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 28, 2018 Category: Research Source Type: news

New vaccine against Bovine Respiratory Disease
: Boehringer Ingelheim reaffirms its focus on preventionBovalto ® Respi Intranasal now registered in most European countries for active immunization of cattle against Bovine Respiratory Syncytial Virus (BRSV) and Bovine Parainfluenza 3 Virus (PI3V), two of the major pathogens involved in Bovine Respiratory Disease (BRD)BRD is one of the most common diseases1 affecting cattle all over the worldBoehringer Ingelheim reaffirms its focus on prevention and animal well-being (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 27, 2018 Category: Research Source Type: news

NSCLC_treatment_sequencing_survey
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC  More than one-third of physicians report not having sufficient information to decide on how to sequence specific targeted lung cancer treatmentsSurvey findings presented today as a late-breaking abstract at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, Canada   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 26, 2018 Category: Research Source Type: news

Lume Meso Phase III Results
Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19th World Conference on Lung Cancer (WCLC 2018)The primary endpoint of progression-free survival was not met in the Phase III LUME-Meso Trial (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 25, 2018 Category: Research Source Type: news

Empa long-term survival benefit
New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular diseaseSurvival estimates from the EMPA-REG OUTCOME ® trial data demonstrate potential long-term benefit of empagliflozin (marketed as Jardiance®) on life expectancy of adults with type 2 diabetes and cardiovascular disease1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 25, 2018 Category: Research Source Type: news

Carmelina
Boehringer Ingelheim and Lilly present full results of Trajenta ®’s CARMELINA® cardiovascular outcome trial Trajenta ® demonstrated a similar long-term cardiovascular and kidney safety profile compared to placebo in adults with type 2 diabetes1 The results of CARMELINA ® were presented at the 54th EASD Annual Meeting today (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 25, 2018 Category: Research Source Type: news

Real-world study reports effects of Spiolto Respimat
Large European real-world study reports effects of Spiolto ® Respimat® for people living with COPD in daily clinical practice1OTIVACTO study reported improvements in both physical functioning and general condition in people living with COPD receiving Spiolto ®(tiotropium/olodaterol) Respimat® therapy14 out of 5 patients reported high satisfaction with their Respimat ® inhaler and tiotropium/olodaterol treatment overall1Data presented at European Respiratory Society International Congress 20181 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 16, 2018 Category: Research Source Type: news

INSTAGE data for nintedanib in advanced IPF published
Clinical trial data for nintedanib in patients with advanced IPF published   INSTAGE ® trial results published in the New England Journal of Medicine1Trial provides clinical data on patients with IPF and severe impairment in gas exchange usually excluded from clinical trials1Efficacy and safety profile of nintedanib in patients with advanced IPF was consistent with that observed in patients with less advanced disease in earlier trials1,2,3,4Sildenafil plus nintedanib did not provide significant benefit   versus nintedanib alone1  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 16, 2018 Category: Research Source Type: news

INPULSIS-ON shows ofev slows progression of IPF
New study results provide evidence that Ofev ® (nintedanib) slows progression of IPF beyond four years with consistent safetyINPULSIS ®-ON study indicates safety and efficacy of Ofev®(nintedanib) are maintained over the long term and consistent with prior findings from INPULSIS® trials1Results from INPULSIS ®-ON, the open-label extension from the two INPULSIS® Phase III trials, published in Lancet Respiratory Medicine1  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 15, 2018 Category: Research Source Type: news

Boehringer Ingelheim acquires all ViraTherapeutics shares
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies  Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeuticsViraTherapeutics will operate in Innsbruck, Austria as a distinct unit of Boehringer Ingelheim ’s Discovery Research organization, maintaining its innovative biotech heritage and close connections to the Medical University of Innsbruck and the regional scientific communityAcquisition strengthens Boehringer Ingelheim ’s commitment to research and development of viral-based immuno-...
Source: Boehringer Ingelheim Corporate News - September 12, 2018 Category: Research Source Type: news

Cyltezo-Phase III -in Psoriasis
Biosimilar Cyltezo ® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasisData show that Cyltezo © (adalimumab- adbm) and Humira®* have similar efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis1At week 16, the study met the primary endpoint, demonstrating clinical equivalence to Humira ®1Data will be presented at the European Association of Dermatology and Venereology Annual Meeting (EADV 2018) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 12, 2018 Category: Research Source Type: news

Changes to the Leadership of Boehringer Ingelheim
’s Corporate Department Medicine (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 10, 2018 Category: Research Source Type: news

The first liquid solution for hypertension in cats
Boehringer Ingelheim launches the first liquid solution for hypertension in catsSemintra ® 10 mg/ml Oral Solution now licenced to treat and control feline hypertensionA new and easy-to-give solution for a common problem in catsBoehringer Ingelheim continues to set new standards of care to strengthen its commitment to animal welfare (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 4, 2018 Category: Research Source Type: news

New Partnership to Develop Novel Treatment Approaches Against Infectious Diseases
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious DiseasesThe new collaboration aims to develop novel breakthrough therapy approaches applying principles of immune modulation to infectious diseases  Immuno-infection is a new focus area of Boehringer Ingelheim ’s Research Beyond Borders (RBB) department, which explores emerging science and technology beyond the company’s core areas of focusBoehringer Ingelheim and Tsinghua University will establish a Joint Research Center for Immuno-Infection for new therapy concept exp...
Source: Boehringer Ingelheim Corporate News - September 3, 2018 Category: Research Source Type: news

Biologicals_BeiGene_NDA_China
Boehringer Ingelheim Biopharmaceuticals China supports BeiGene in its China NDA submission of anti-PD-1 antibody, tislelizumabFirst biologic manufactured by Boehringer Ingelheim BioChina accepted for New Drug Application reviewImportant milestone for Boehringer Ingelheims ’ collaboration partner BeiGene in immuno-oncologyBoehringer Ingelheim BioChina is proud to support BeiGene in serving patients worldwide with this important medicine   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 3, 2018 Category: Research Source Type: news

new_solids_tablet_ launch_facility_ingelheim
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 21, 2018 Category: Research Source Type: news

Canbridge_contract_bio_manufacturing
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 20, 2018 Category: Research Source Type: news

New data at ESC supports Pradaxa safety profile
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 16, 2018 Category: Research Source Type: news

GioTag
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 8, 2018 Category: Research Source Type: news

New Partnership to Develop Gene Therapy for Cystic Fibrosis
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 6, 2018 Category: Research Source Type: news

Boehringer Ingelheim launches the initiative InReachAfrica
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 30, 2018 Category: Research Source Type: news

H1
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 30, 2018 Category: Research Source Type: news

CARMELINA high level
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 16, 2018 Category: Research Source Type: news

New production center for Veterinary Public Health
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 10, 2018 Category: Research Source Type: news

Biologicals_fill_finish_Shanghai
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 3, 2018 Category: Research Source Type: news

CHMP Positive Opinion
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 28, 2018 Category: Research Source Type: news